Efficacy of tocilizumab treatment in cerulein-induced experimental acute pancreatitis model in rats
Acute pancreatitis (AP) is a disease that can cause local and systemic complications that may have high morbidity and mortality. Currently, there is not any specific treatment for AP. In this study, we created an experimental model of AP in rats, and we aimed to demonstrate the histological effectiv...
Gespeichert in:
| Veröffentlicht in: | The Turkish journal of gastroenterology 2017-11, Vol.28 (6), p.485-491 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 491 |
|---|---|
| container_issue | 6 |
| container_start_page | 485 |
| container_title | The Turkish journal of gastroenterology |
| container_volume | 28 |
| creator | Hançerli, Yusuf Kaplan, Mustafa Tanoğlu, Alpaslan Yeşilbaş, Soner Küçükodacı, Zafer Yıldırım, Muhammet Narlı, Gizem Sakin, Yusuf Serdar |
| description | Acute pancreatitis (AP) is a disease that can cause local and systemic complications that may have high morbidity and mortality. Currently, there is not any specific treatment for AP. In this study, we created an experimental model of AP in rats, and we aimed to demonstrate the histological effectiveness of tocilizumab treatment that antagonizes interleukin-6 (IL-6), one of the key cytokines in the development of AP.
Forty-eight rats were divided into six groups for this study. AP model was created by subcutaneous injections of cerulein (20 μg/kg) four times at 1-h intervals. Tocilizumab 4 mg/kg was administered to one of the treatment groups and 8 mg/kg to the other treatment group intraperitoneally. The effects of tocilizumab were revealed by examining pancreatic tissue of the rats histopathologically according to the Schonberg scoring system.
A comparison between tocilizumab treatment group and AP control group provides statistically significant improvement in AP (p |
| doi_str_mv | 10.5152/tjg.2017.16738 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_cross</sourceid><recordid>TN_cdi_gale_infotracmisc_A559688410</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A559688410</galeid><sourcerecordid>A559688410</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-3b4239c8eff943f88f910f6c3b9b91ccffe718bcecefbfb8fadcd717d5ce8df63</originalsourceid><addsrcrecordid>eNptkU1LxDAQhoMo7rp69SgBz12Tpk3T47L4BQte9FzSycySpR9Lm4Lrr7d11dOSw0DmfQZmHsZupVimMo0fwm67jIXMllJnypyxeSwTE6VaZOdsLpUQUZInZsau-n4nhDJSx5dsFufC6EzqOYNHIg8WDrwlHlrwlf8aalvy0KENNTaB-4YDdkOFvol84wZAx_Fzj52f2rbiFoaAfG8bmBgffM_r1mE1kZ0N_TW7IFv1ePNbF-zj6fF9_RJt3p5f16tNBErHIVJlEqscDBLliSJjKJeCNKgyL3MJQISZNCUgIJVUGrIOXCYzlwIaR1ot2P1x7tZWWPiG2tBZqH0PxSpNc21MIsWYWp5Ijc9h7aFtkPz4fwqAru37DqnYj6vb7lBIUUwSilFCMUkofiSMwN0R2A9lje4__nd19Q2MdoVq</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Efficacy of tocilizumab treatment in cerulein-induced experimental acute pancreatitis model in rats</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Hançerli, Yusuf ; Kaplan, Mustafa ; Tanoğlu, Alpaslan ; Yeşilbaş, Soner ; Küçükodacı, Zafer ; Yıldırım, Muhammet ; Narlı, Gizem ; Sakin, Yusuf Serdar</creator><creatorcontrib>Hançerli, Yusuf ; Kaplan, Mustafa ; Tanoğlu, Alpaslan ; Yeşilbaş, Soner ; Küçükodacı, Zafer ; Yıldırım, Muhammet ; Narlı, Gizem ; Sakin, Yusuf Serdar</creatorcontrib><description>Acute pancreatitis (AP) is a disease that can cause local and systemic complications that may have high morbidity and mortality. Currently, there is not any specific treatment for AP. In this study, we created an experimental model of AP in rats, and we aimed to demonstrate the histological effectiveness of tocilizumab treatment that antagonizes interleukin-6 (IL-6), one of the key cytokines in the development of AP.
Forty-eight rats were divided into six groups for this study. AP model was created by subcutaneous injections of cerulein (20 μg/kg) four times at 1-h intervals. Tocilizumab 4 mg/kg was administered to one of the treatment groups and 8 mg/kg to the other treatment group intraperitoneally. The effects of tocilizumab were revealed by examining pancreatic tissue of the rats histopathologically according to the Schonberg scoring system.
A comparison between tocilizumab treatment group and AP control group provides statistically significant improvement in AP (p<0.0001). Furthermore, the dose of 8 mg/kg is shown to be more effective than 4 mg/kg (p=0.004).
Our study points out that tocilizumab may be an effective agent for pancreatitis treatment.</description><identifier>ISSN: 1300-4948</identifier><identifier>EISSN: 2148-5607</identifier><identifier>DOI: 10.5152/tjg.2017.16738</identifier><identifier>PMID: 29086716</identifier><language>eng</language><publisher>Turkey: AVES</publisher><subject>Acute Disease ; Animals ; Antibodies, Monoclonal, Humanized - administration & dosage ; Ceruletide ; Complications and side effects ; Disease Models, Animal ; Dose-Response Relationship, Drug ; Gastrointestinal Agents - administration & dosage ; Interleukins ; Pancreas - drug effects ; Pancreas - pathology ; Pancreatitis ; Pancreatitis - chemically induced ; Pancreatitis - drug therapy ; Pancreatitis - pathology ; Rats</subject><ispartof>The Turkish journal of gastroenterology, 2017-11, Vol.28 (6), p.485-491</ispartof><rights>COPYRIGHT 2017 AVES</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-3b4239c8eff943f88f910f6c3b9b91ccffe718bcecefbfb8fadcd717d5ce8df63</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27933,27934</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29086716$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hançerli, Yusuf</creatorcontrib><creatorcontrib>Kaplan, Mustafa</creatorcontrib><creatorcontrib>Tanoğlu, Alpaslan</creatorcontrib><creatorcontrib>Yeşilbaş, Soner</creatorcontrib><creatorcontrib>Küçükodacı, Zafer</creatorcontrib><creatorcontrib>Yıldırım, Muhammet</creatorcontrib><creatorcontrib>Narlı, Gizem</creatorcontrib><creatorcontrib>Sakin, Yusuf Serdar</creatorcontrib><title>Efficacy of tocilizumab treatment in cerulein-induced experimental acute pancreatitis model in rats</title><title>The Turkish journal of gastroenterology</title><addtitle>Turk J Gastroenterol</addtitle><description>Acute pancreatitis (AP) is a disease that can cause local and systemic complications that may have high morbidity and mortality. Currently, there is not any specific treatment for AP. In this study, we created an experimental model of AP in rats, and we aimed to demonstrate the histological effectiveness of tocilizumab treatment that antagonizes interleukin-6 (IL-6), one of the key cytokines in the development of AP.
Forty-eight rats were divided into six groups for this study. AP model was created by subcutaneous injections of cerulein (20 μg/kg) four times at 1-h intervals. Tocilizumab 4 mg/kg was administered to one of the treatment groups and 8 mg/kg to the other treatment group intraperitoneally. The effects of tocilizumab were revealed by examining pancreatic tissue of the rats histopathologically according to the Schonberg scoring system.
A comparison between tocilizumab treatment group and AP control group provides statistically significant improvement in AP (p<0.0001). Furthermore, the dose of 8 mg/kg is shown to be more effective than 4 mg/kg (p=0.004).
Our study points out that tocilizumab may be an effective agent for pancreatitis treatment.</description><subject>Acute Disease</subject><subject>Animals</subject><subject>Antibodies, Monoclonal, Humanized - administration & dosage</subject><subject>Ceruletide</subject><subject>Complications and side effects</subject><subject>Disease Models, Animal</subject><subject>Dose-Response Relationship, Drug</subject><subject>Gastrointestinal Agents - administration & dosage</subject><subject>Interleukins</subject><subject>Pancreas - drug effects</subject><subject>Pancreas - pathology</subject><subject>Pancreatitis</subject><subject>Pancreatitis - chemically induced</subject><subject>Pancreatitis - drug therapy</subject><subject>Pancreatitis - pathology</subject><subject>Rats</subject><issn>1300-4948</issn><issn>2148-5607</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkU1LxDAQhoMo7rp69SgBz12Tpk3T47L4BQte9FzSycySpR9Lm4Lrr7d11dOSw0DmfQZmHsZupVimMo0fwm67jIXMllJnypyxeSwTE6VaZOdsLpUQUZInZsau-n4nhDJSx5dsFufC6EzqOYNHIg8WDrwlHlrwlf8aalvy0KENNTaB-4YDdkOFvol84wZAx_Fzj52f2rbiFoaAfG8bmBgffM_r1mE1kZ0N_TW7IFv1ePNbF-zj6fF9_RJt3p5f16tNBErHIVJlEqscDBLliSJjKJeCNKgyL3MJQISZNCUgIJVUGrIOXCYzlwIaR1ot2P1x7tZWWPiG2tBZqH0PxSpNc21MIsWYWp5Ijc9h7aFtkPz4fwqAru37DqnYj6vb7lBIUUwSilFCMUkofiSMwN0R2A9lje4__nd19Q2MdoVq</recordid><startdate>20171101</startdate><enddate>20171101</enddate><creator>Hançerli, Yusuf</creator><creator>Kaplan, Mustafa</creator><creator>Tanoğlu, Alpaslan</creator><creator>Yeşilbaş, Soner</creator><creator>Küçükodacı, Zafer</creator><creator>Yıldırım, Muhammet</creator><creator>Narlı, Gizem</creator><creator>Sakin, Yusuf Serdar</creator><general>AVES</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20171101</creationdate><title>Efficacy of tocilizumab treatment in cerulein-induced experimental acute pancreatitis model in rats</title><author>Hançerli, Yusuf ; Kaplan, Mustafa ; Tanoğlu, Alpaslan ; Yeşilbaş, Soner ; Küçükodacı, Zafer ; Yıldırım, Muhammet ; Narlı, Gizem ; Sakin, Yusuf Serdar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-3b4239c8eff943f88f910f6c3b9b91ccffe718bcecefbfb8fadcd717d5ce8df63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Acute Disease</topic><topic>Animals</topic><topic>Antibodies, Monoclonal, Humanized - administration & dosage</topic><topic>Ceruletide</topic><topic>Complications and side effects</topic><topic>Disease Models, Animal</topic><topic>Dose-Response Relationship, Drug</topic><topic>Gastrointestinal Agents - administration & dosage</topic><topic>Interleukins</topic><topic>Pancreas - drug effects</topic><topic>Pancreas - pathology</topic><topic>Pancreatitis</topic><topic>Pancreatitis - chemically induced</topic><topic>Pancreatitis - drug therapy</topic><topic>Pancreatitis - pathology</topic><topic>Rats</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hançerli, Yusuf</creatorcontrib><creatorcontrib>Kaplan, Mustafa</creatorcontrib><creatorcontrib>Tanoğlu, Alpaslan</creatorcontrib><creatorcontrib>Yeşilbaş, Soner</creatorcontrib><creatorcontrib>Küçükodacı, Zafer</creatorcontrib><creatorcontrib>Yıldırım, Muhammet</creatorcontrib><creatorcontrib>Narlı, Gizem</creatorcontrib><creatorcontrib>Sakin, Yusuf Serdar</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>The Turkish journal of gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hançerli, Yusuf</au><au>Kaplan, Mustafa</au><au>Tanoğlu, Alpaslan</au><au>Yeşilbaş, Soner</au><au>Küçükodacı, Zafer</au><au>Yıldırım, Muhammet</au><au>Narlı, Gizem</au><au>Sakin, Yusuf Serdar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of tocilizumab treatment in cerulein-induced experimental acute pancreatitis model in rats</atitle><jtitle>The Turkish journal of gastroenterology</jtitle><addtitle>Turk J Gastroenterol</addtitle><date>2017-11-01</date><risdate>2017</risdate><volume>28</volume><issue>6</issue><spage>485</spage><epage>491</epage><pages>485-491</pages><issn>1300-4948</issn><eissn>2148-5607</eissn><abstract>Acute pancreatitis (AP) is a disease that can cause local and systemic complications that may have high morbidity and mortality. Currently, there is not any specific treatment for AP. In this study, we created an experimental model of AP in rats, and we aimed to demonstrate the histological effectiveness of tocilizumab treatment that antagonizes interleukin-6 (IL-6), one of the key cytokines in the development of AP.
Forty-eight rats were divided into six groups for this study. AP model was created by subcutaneous injections of cerulein (20 μg/kg) four times at 1-h intervals. Tocilizumab 4 mg/kg was administered to one of the treatment groups and 8 mg/kg to the other treatment group intraperitoneally. The effects of tocilizumab were revealed by examining pancreatic tissue of the rats histopathologically according to the Schonberg scoring system.
A comparison between tocilizumab treatment group and AP control group provides statistically significant improvement in AP (p<0.0001). Furthermore, the dose of 8 mg/kg is shown to be more effective than 4 mg/kg (p=0.004).
Our study points out that tocilizumab may be an effective agent for pancreatitis treatment.</abstract><cop>Turkey</cop><pub>AVES</pub><pmid>29086716</pmid><doi>10.5152/tjg.2017.16738</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1300-4948 |
| ispartof | The Turkish journal of gastroenterology, 2017-11, Vol.28 (6), p.485-491 |
| issn | 1300-4948 2148-5607 |
| language | eng |
| recordid | cdi_gale_infotracmisc_A559688410 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Acute Disease Animals Antibodies, Monoclonal, Humanized - administration & dosage Ceruletide Complications and side effects Disease Models, Animal Dose-Response Relationship, Drug Gastrointestinal Agents - administration & dosage Interleukins Pancreas - drug effects Pancreas - pathology Pancreatitis Pancreatitis - chemically induced Pancreatitis - drug therapy Pancreatitis - pathology Rats |
| title | Efficacy of tocilizumab treatment in cerulein-induced experimental acute pancreatitis model in rats |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-02T00%3A34%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20tocilizumab%20treatment%20in%20cerulein-induced%20experimental%20acute%20pancreatitis%20model%20in%20rats&rft.jtitle=The%20Turkish%20journal%20of%20gastroenterology&rft.au=Han%C3%A7erli,%20Yusuf&rft.date=2017-11-01&rft.volume=28&rft.issue=6&rft.spage=485&rft.epage=491&rft.pages=485-491&rft.issn=1300-4948&rft.eissn=2148-5607&rft_id=info:doi/10.5152/tjg.2017.16738&rft_dat=%3Cgale_cross%3EA559688410%3C/gale_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/29086716&rft_galeid=A559688410&rfr_iscdi=true |